Treats infections caused by penicillinase-producing staphylococci. ANDA 90560, held by Antibiotice. Nafcillin Sodium.
As of Nov 16, 2026, ANDA 90560 (Nafcillin Sodium), held by Antibiotice, was first approved by FDA on Oct 3, 2011, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see CLINICAL PHARMACOLOGY – Susceptibility Test Methods ). Nafcillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to methicillin-resistant Staphylococcus sp., therapy with Nafcillin for Injection should be discontinued and alternative therapy provided.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 3, 2011 | Original application | Approved | None posted |
| Nafcillin SodiumEQ 1GM BASE/VIAL · injectable;injection | Nafcillin Sodium | Rx |
| Nafcillin SodiumEQ 2GM BASE/VIAL · injectable;injection | Nafcillin Sodium | Rx |
| Dec 6, 2022 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 27, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 27, 2021 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 3, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters